Skip to main content

Patrick S. Dakum, MBBS, MPH

Academic Title:

Assistant Professor

Primary Appointment:

Epidemiology & Public Health

Additional Title:

Assistant Professor, Epidemiology & Prevention, Institute Of Human Virology; Chief Executive Officer, Institute of Human Virology, Nigeria (IHVN)

Location:

725 W. Lombard Street, , Baltimore, MD 21201

Phone (Primary):

410-706-1948

Phone (Secondary):

+234-9-46103420

Fax:

410-706-1944

Education and Training

1977                A-levels, School of Basic Studies, Ahmadu Bello University, Nigeria                     

1982                M.B.B.S., Ahmadu Bello Teaching Hospital, Zaria, Nigeria

1990                M.P.H., Lagos University Teaching Hospital, Lagos, Nigeria

Biosketch

Dr. Patrick Dakum is an Assistant Professor in the Department of Epidemiology and Preventive Medicine at the University of Maryland School of Medicine, Baltimore, USA.  As a public health physician and Chief Executive Officer of the Institute of Human Virology, Nigeria, he has led the Institute to provide HIV counseling and testing for 8.3 million individuals, anti-retroviral prophylaxis for over 85,000 pregnant women, and enrolment of more than 465,000 people into the HIV care program and over 3,000 multi-drug resistant patients into treatment. He obtained his medical degree from the Ahmadu Bello University, Zaria in Nigeria and subsequently his Master’s Degree in Public Health at the Lagos University Teaching Hospital, Nigeria.

Research/Clinical Keywords

Implementation Science Research, HIV, MDR TB and non-communicable diseases (NCDs)

Highlighted Publications

  1. Ssemwanga D, Lihana RW, Ugoji C, Abimiku A, Nkengasong J, Dakum P, Ndembi N. Update on HIV-1 acquired and transmitted drug resistance in Africa. AIDS Rev. 2015 Jan-Mar;17(1):3-20. Review. PubMed PMID: 25427100.
  2. Abubakar A, Ndembi N, Ogbanufe O, Inalegwu A, Wilson S, Ebagua I, Peters S, Chime C, Dakum P, Abimiku AG. Improved Performance of COBAS AmpliPrep/COBAS TaqMan Version 2.0 Assay Over Amplicor Monitor Version 1.5 in the Quantification  of HIV-1 RNA Viral Load in Abuja, Nigeria. Curr HIV Res. 2015;13(4):262-7.
  3. Avong YK, van Wyk B, Njab J, Abimiku AG, Ndembi N, Okuma J, Ogbanufe O, Ekong E, Dakum P, Blattner WA. Adherence to Anti-Retroviral Therapy in North Central Nigeria. Curr HIV Res. 2015;13(4):268-78. PubMed PMID: 25642849.
  4. Ugoji C, Okere N, Dakum P, Ake-Uzoigwe R, Igboelina D, Ndembi N, Ekong E, Charurat M, Blattner WA. Correlates of Patient Retention in HIV Care and Treatment Programs in Nigeria. Curr HIV Res. 2015;13(4):300-7. PubMed PMID:25777516.
  5. Avong YK, Isaakidis P, Hinderaker SG, Van den Bergh R, Ali E, Obembe BO, Ekong E, Adebamowo C, Ndembi N, Okuma J, Osakwe A, Oladimeji O, Akang G, Obasanya JO, Eltayeb O, Agbaje AV, Abimiku A, Mensah CO, Dakum PS. Doing no harm? Adverse  events in a nation-wide cohort of patients with multidrug-resistant tuberculosis  in Nigeria. PLoS One. 2015 Mar 17;10(3):e0120161. doi: 10.1371/journal.pone.0120161. PubMed PMID: 25781958; PubMed Central PMCID:PMC4364363.
  6. Nwofor AC, Nyamngee A, Nwabuisi C, Iwakun M, Gidado M, Mensah C, Dakum P, Agbede OO, Ndembi N, Blattner WA, Abimiku AG. Performance of Genotype MTBDRplus in the Detection of Resistance to Rifampicin and Isoniazid Among Clinical Mycobacteria Isolates in Ilorin, Nigeria. Curr HIV Res. 2015;13(4):308-14. PubMed PMID: 25845392.
  7. Coker M, Etiebet MA, Chang H, Awwal G, Jumare J, Musa BM, Babashani M, Habib AG, Dakum P, Abimiku AG, Charurat ME, Blattner WA, Eng M, Ndembi N. Socio-Demographic and Adherence Factors Associated with Viral Load Suppression in HIV-Infected Adults Initiating Therapy in Northern Nigeria: A Randomized Controlled Trial of a Peer Support Intervention. Curr HIV Res. 2015;13(4):279-85. PubMed PMID: 25845393.
  8. Jatau B, Avong Y, Ogundahunsi O, Shah S, Tayler Smith K, Van den Bergh R, Zachariah R, van Griensven J, Ekong E, Dakum P. Procurement and Supply Management System for MDR-TB in Nigeria: Are the Early Warning Targets for Drug Stock Outs and Over Stock of Drugs Being Achieved? PLoS One. 2015 Jun 22;10(6):e0128500. doi: 10.1371/journal.pone.0128500. PubMed PMID: 26098673.
  9. Jedy-Agba EE, Oga EA, Odutola M, Abdullahi YM, Popoola A, Achara P, Afolayan E, Banjo AA, Ekanem IO, Erinomo O, Ezeome E, Igbinoba F, Obiorah C, Ogunbiyi O, Omonisi A, Osime C, Ukah C, Osinubi P, Hassan R, Blattner W, Dakum P, Adebamowo CA. Developing National Cancer Registration in Developing Countries - Case Study  of the Nigerian National System of Cancer Registries. Front Public Health. 2015 Jul 30;3:186.
  10. Onovo AA, Nta IE, Onah AA, Okolo CA, Aliyu A, Dakum P, Atobatele AO, Gado P. Partner HIV serostatus disclosure and determinants of serodiscordance among prevention of mother to child transmission clients in Nigeria. BMC Public Health. 2015 Aug 28;15:827.
  11. Dareng EO, Jedy-Agba E, Bamisaye P, Isa Modibbo F, Oyeneyin LO, Adewole AS, Olaniyan OB, Dakum PS, Pharoah PD, Adebamowo CA. Influence of Spirituality and Modesty on Acceptance of Self-Sampling for Cervical Cancer Screening. PLoS One. 2015 Nov 3;10(11):e0141679. doi: 10.1371/journal.pone.0141679.
  12. Dareng EO, Ma B, Famooto AO, Akarolo-Anthony SN, Offiong RA, Olaniyan O, Dakum PS, Wheeler CM, Fadrosh D, Yang H, Gajer P, Brotman RM, Ravel J, Adebamowo CA. Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women. Epidemiol Infect. 2016 Jan;144(1):123-37. doi: 10.1017/S0950268815000965. PubMed PMID: 26062721; PubMed Central PMCID: PMC4659743.
  13. Oga EA, Schumaker LM, Alabi BS, Obaseki D, Umana A, Bassey IA, Ebughe G, Oluwole O, Akeredolu T, Adebamowo SN, Dakum P, Cullen K, Adebamowo CA. Paucity of HPV-Related Head and Neck Cancers (HNC) in Nigeria. PLoS One. 2016 Apr 6;11(4):e0152828. doi: 10.1371/journal.pone.0152828.
  14. Oga EA, Brown JP, Brown C, Dareng E, Adekanmbi V, Odutola M, Olaniyan O, Offiong R, Obende K, Adewole AS, Peter A, Dakum P, Adebamowo C. Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women. BMC Womens Health. 2016 May 11;16:25. doi:10.1186/s12905-016-0304-8.
  15. Inalegwu A, Phillips S, Datir R, Chime C, Ozumba P, Peters S, Ogbanufe O, Mensah C, Abimiku A, Ndembi N, Dakum P. Active tracking of rejected dried blood samples in a large program in Nigeria. World J Virol. 2016 May 12;5(2):73-81. doi: 10.5501/wjv.v5.i2.73. PubMed PMID: 27175352; PubMed Central PMCID:PMC4861873.
  16. Ezeanolue EE, Powell BJ, Patel D, Olutola A, Obiefune M, Dakum P, Okonkwo P, Gobir B, Akinmurele T, Nwandu A, Torpey K, Oyeledum B, Aina M, Eyo A, Oleribe O, Ibanga I, Oko J, Anyaike C, Idoko J, Aliyu MH, Sturke R, Watts H, Siberry G; Nigeria Implementation Science Alliance.. Identifying and Prioritizing Implementation Barriers, Gaps, and Strategies Through the Nigeria Implementation Science Alliance: Getting to Zero in the Prevention of Mother-to-Child Transmission of HIV. J Acquir Immune Defic Syndr. 2016 Aug 1;72 Suppl 2:S161-6.
  17.  Akinwande O, Bashorun A, Azeez A, Agbo F, Dakum P, Abimiku A, Bilali C, Idoko J, Ogungbemi K. A Decade of Monitoring HIV Epidemics in Nigeria: Positioning for Post-2015 Agenda. AIDS Behav. 2016 Nov 14. [Epub ahead of print] PubMed PMID: 27844297.
  18. Adebamowo SN, Dareng EO, Famooto AO, Offiong R, Olaniyan O, Obende K, Adebayo A, Ologun S, Alabi B, Achara P, Bakare RA, Odutola M, Olawande O, Okuma J, Odonye G, Adebiyi R, Dakum P, Adebamowo CA; ACCME Research Group as part of the H3Africa Consortium. Cohort Profile: African Collaborative Center for Microbiome and Genomics Research's (ACCME) Human Papillomavirus (HPV) and Cervical Cancer Study. Int J Epidemiol. 2017 Apr 13. doi: 10.1093/ije/dyx050. [Epub ahead of print]PubMed PMID: 28419249.
  19. Odume B, I. Pathmanathan, S. Pals, K. Dokubo, Ogbanufe O, D. Onotu, A. Date, Okuma J, E. Okpoko, S. Dutt, E. Ekong, E. Asadu, N. Chukwurah, P. Dakum, H. Tomlinson. Assessment of Uptake of Antiretroviral Therapy among HIV-Infected TB Patients in Nigeria. Universal Journal of Public Health 5(5): 248-255, 2017.
  20. Egbe CO, Dakum PS, Ekong E, Kohrt BA, Minto JG, Ticao CJ. Depression, suicidality, and alcohol use disorder among people living with HIV/AIDS in Nigeria. BMC Public Health. 2017 Jun 2;17(1):542. doi: 10.1186/s12889-017-4467-5.PubMed PMID: 28577548; PubMed Central PMCID: PMC5457576.
  21. Volz EM, Ndembi N, Nowak R, Kijak GH, Idoko J, Dakum P, Royal W, Baral S, Dybul M, Blattner WA, Charurat M. Phylodynamic analysis to inform prevention efforts in mixed HIV epidemics. Virus Evol. 2017 Jul 28;3(2):vex014. doi: 10.1093/ve/vex014. eCollection 2017 Jul. PubMed PMID: 28775893; PubMed Central PMCID: PMC5534066.
  22. Dapiap, S. B., Adelekan, B. A., Ndembi, N., Murtala-Ibrahim, F., Dakum, P. S., & Aliyu, A. T. Immunological and clinical assessment of adult HIV patients following switch to second-line antiretroviral regimen in a large HIV Program in North-central Nigeria. Journal of AIDS and HIV Research, 2017 Jun 30: 9(5), 106-116.
  23. Onuka, O., Ahukanna, J., Okebaram, C., Dakum, P., Agbaje, A., Ibeziako, V., Mustapha, G., Chukwueme, N., Anago, C., Ubochioma, E., Okorie, A., Bethrand, O. and Charles, N. A Case Study of Multi Drug-Resistant Tuberculosis (MDR-TB), HIV and Diabetes Mellitus (Dm) Comorbidity: Triple Pathology; Challenges and Prospects. Advances in Infectious Diseases, 2017 Sep : 7 (3), 70-79.

Additional Publication Citations

Complete List of Published Work in MyBibliography:   https://www.ncbi.nlm.nih.gov/pmc/?term=patrick+dakum

Grants and Contracts

07/01/15– 06/30/19                 PI (10%)

NGA-T-IHVN Global Fund MDR-TB – P2   

Global Fund

Annual Direct Costs: $32,042,851

Total Direct Costs:      $112,149,978 

 

03/01/17 – 12/30/19                PI (5%)                                               

NGA-H- FHI-360 Global Fund HIV SR

Annual Direct Costs: $5,103,712

Total Direct Costs:      $12,759,280

 

09/30/17 - 09/29/22                 PI (60%)

Achieving HIV Epidemic Control

US Centers for Disease Control and Prevention, U2G GH002099-01, PA GH17-1753

Annual Direct Costs: $24, 994,350.00

Total Direct Costs:      $125,000,000.00

Professional Activity

1982 – 1983                House Officer, Jos University Teaching Hospital, Jos, Nigeria

1983 – 1984                Medical Officer i/c, Comprehensive Health Centre Akure

1984 – 1985                Medical Superintendent i/c, General Hospital Lafiya

1986 – 1993                Principal Medical Officer, Nigerian Telecommunications (NITEL) Plc

1993 – 1997                Regional Program Manager, Access to Safe and Voluntary Contraception (AVSC)/USAID Jos Nigeria

1998 – 1999                Public Health Consultant, Help International – Jos Nigeria

2000 – 2001                Program Adviser, United Nations Population Fund (UNFPA) – Bauchi Nigeria

2001 – 2002                Regional Program Manager, Centre for Development and Population Activity (CEDPA)-USAID

2002 – 2003                Commissioner – Information, Government of Plateau State, Nigeria

2003 – 2004                Commissioner – Health, Government of Plateau State, Nigeria

2004                            Program Director, Institute of Human Virology Nigeria, Abuja, Nigeria

2004 – present             Chief Executive Officer, Institute of Human Virology Nigeria, Abuja, Nigeria

2005 – 20012              Adjunct Professor, Department of Epidemiology and Public Health, University of Maryland School of Medicine

2012 – present            Assistant Professor, Department of Epidemiology and Public Health, University of Maryland School of Medicine  

Links of Interest

Insitute of Human Virology http://www.ihv.org/

Institue of Human Virology, Nigiera  http://ihvnigeria.org/ihvnweb/webnew/

International Research Center of Excellence (IRCE) http://ihvnigeria.org/ihvnweb/webnew/index.php/officesdepts/training/training.html

Nigeria Implementation Science Alliance https://www.nisaresearch.org/